Palantir Technologies raises its full-year outlook but the stock falls, Ford suspends guidance because of uncertainty over ...

Hims & Hers Health ( HIMS) shares surged 8% Tuesday, a day after the health and wellness platform posted better-than-expected ...

Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.

Hims & Hers Health first-quarter revenue more than doubled as subscribers rose 38%, while its second-quarter sales outlook ...

Hims & Hers shares fell in extended trading on Monday after the company reported first-quarter earnings that offered soft ...

Hims & Hers launched a pharmacy-made weight-loss drug last year, taking advantage of an FDA rule allowing it to temporarily ...

Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...

The company reported adjusted earnings per share of $0.28 on revenue of $586 million – a significant rise compared to last ...

Hims & Hers Health (NYSE:HIMS) reported a strong financial performance for Q1 2025, with revenue reaching $586 million, ...

Hims & Hers' first-quarter 2025 performance reflects continued strength in its online revenue channel on the back of solid product demand and an increasing subscriber base.

Hims & Hers Health reports strong Q1 results with 111% revenue growth, 38% subscriber growth, and sets 2030 targets. Read ...